International Framework for Cancer Patient Advocacy: Empowering Organizations and Patients to Create a National Call to Action on Cancer

Rebekkah M. Schear, Leigh Manasco, Devon McGoldrick, Kiti Kajana, Lauren Rosenthal, Ann McMikel, and Nancy Lins. LIVESTRONG Foundation, Austin, TX; Leigh Manasco, LIVESTRONG Foundation, Memphis, TN; Kiti Kajana, Open Society Foundations, New York, NY; Lauren Rosenthal and Ann McMikel, American Cancer Society, and Nancy Lins, N.E. Lins & Associates, Atlanta, GA.

Authors’ disclosures of potential conflicts of interest and contributions are found at the end of this article.

Corresponding author: Rebekkah M. Schear, MIA, LIVESTRONG Foundation, 2201 East 6th St, Austin, TX 78705; e-mail: rebekkah.schea@livestrong.org.

INTRODUCTION

Cancer is a leading cause of death around the world. The global cancer community has acknowledged that without significant efforts, rates of new cancer cases could rise from 14 to 22 million annually in the next two decades. Advocacy plays a pivotal role in cancer control planning and is necessary in any resource setting to influence policy and improve delivery of cancer control. The WHO 2008 practical guide on cancer control policy and advocacy and 2013 to 2020 Global Action Plan for the Prevention and Control of Noncommunicable Diseases (NCDs) both articulate that advocacy is a critical strategy in improving cancer control and care delivery nationally and globally.

Patients with cancer, survivors, and caregivers are in an ideal position to provide insight into gaps within systems of care. Through capacity building, their voices are a powerful tool in advocating for improvements in knowledge, practice, policy, and services and in empowering others to share their stories. Moreover, cancer patient advocacy supports national efforts toward achievement of NCD and cancer control targets, such as those outlined in the Global Action Plan and in the World Cancer Declaration. This article presents a framework for empowering patients, survivors, and organizations to implement a comprehensive, patient-informed national call to action on cancer through planning, implementing, and leveraging outcomes of a patient forum.

CONCEPT OF CANCER PATIENT ADVOCACY

Definitions of cancer patient advocacy vary in the literature; here, we define this advocacy as a...
Figure 1. – Components of conceptual framework. Policy environment can change from highly restrictive to receptive, and throughout a long-term advocacy campaign, varying strategies will be used to adapt to the evolving political environment. It is therefore critical to assess environment in advance of planning advocacy effort to maximize potential impact.

**ORIGINS AND THE GROWING GLOBAL MOVEMENT**

The history of cancer patient advocacy varies globally. In the West, it has had a robust history over the last 30 years. In the United States in particular, it has roots in the successful civil, women’s, human, and consumer rights and HIV/AIDS advocacy movements. Pioneering organizations of cancer advocacy, such as American Cancer Society, began implementing patient engagement activities as early as the 1950s (with Reach to Recovery program), and others like Susan G. Komen for the Cure and the National Coalition for Cancer Survivorship launched major activities in the 1980s and 1990s. Rapid growth of these activities, particularly among breast cancer organizations, successfully led to policy changes to benefit survivors, improvement in awareness about survivorship, and the introduction of survivor-driven research.

Over the last few decades, cancer advocacy in the United States has led to advocate groups gaining significant influence over policymakers, researchers, and health care providers and has become a critical part of the shift in the health care paradigm from illness-centered to patient-centered care, where patients and families are more actively participating in their care and in the creation of services and policies.

Although organizations in countries such as Indonesia, Egypt, Canada, Chile, and the United Kingdom have engaged in cancer advocacy for more than 15 years, in many other countries, cancer advocacy is a more novel concept. The ethos and language of advocacy lack consistency across many cultures, and the word for advocacy is often not translatable directly. That said, there is current growth in advocacy activities in many low- and middle-income countries (LMICs), particularly in Africa and Latin America. This burgeoning activity is evident in the context of the massive call to action issued through the 2011 United Nations Summit on NCDs and the resulting Global Action Plan, Monitoring Framework, and Global Coordination Mechanism, which have evolved as part of the large-scale response to NCD and cancer problems.

The WHO reported that as of 2010, 107 countries had national operational policies or action plans for cancer. However, the reality at the local level, especially in LMICs, is that there remains a dearth of infrastructure to address cancer, and it is
likely that physical, emotional, and practical needs of patients are not being fully met. Patient advocacy can improve access to treatment, raise awareness of the value of prevention, and ensure that patient viewpoints are integrated into planning and policy.

PATIENT FORUMS

Cancer patient forums are stakeholder meetings addressing a broad range of quality-of-life and survivorship issues. The objectives of forums are determined by local stakeholders but may include providing data, raising awareness of key system issues from the patient perspective, or improving resources and infrastructure. Forums convene dynamic groups of stakeholders like nongovernmental organization (NGO) leaders, patients, survivors, caregivers, health care professionals, media, government leaders, and researchers to dialogue.

The implementation of structured patient forums was undertaken by the Union for International Cancer Control (UICC) in 2004, as a result of reports of similar successful initiatives in France and Italy in the late 1990s, and was based on the impact of the US President’s Cancer Panels. We built on this initial concept by expanding the best practices of the UICC and creating a structured, replicable framework for patient forum implementation.

The International Patient Advocacy Framework (IPAF) was developed to support a comprehensive, patient-informed national call to action on cancer through planning, implementing, and leveraging the outcomes of patient forums. It proposed elevating patient and survivor voices to bring visibility to gaps in cancer control and highlight the need for cancer to be a higher priority on national health agendas.

Long-term outcomes of implementation of the IPAF are two-fold: 1) contribution toward addressing needs of patients with cancer nationally through improvements in attitudes, knowledge, practice, policy, systems, and services; and 2) national development of a new or existing patient advocacy movement.

METHODS

Figure 1 presents the IPAF. The framework was developed over 4 years through implementation of two pilot projects in different countries. Using the program evaluation of the UICC, we created a series of trainings and tools to build the capacity of local NGOs, patients, and survivors to plan and implement a patient forum and to create and disseminate a national call to action. Pilot countries were selected based on criteria including: substantial cancer incidence and survivorship rates, some history of advocacy, basic level of care infrastructure, base of cancer civil society organizations, and strong media infrastructure. South Africa and Japan were selected with the intent of testing the framework in different contexts.

The framework was piloted in South Africa from 2009 to 2011, and results were measured through postproject surveys completed by members of the collaborative working group and interviews with the in-country partner (lead agency). Results from surveys were analyzed, and minor changes were made to the framework. It was then piloted in Japan from 2012 to 2014. Results were measured again in the same means.

In both countries, the first step in launching the project was to select a lead agency with responsibility for building a working group to support planning and implementation of the forum, launching a call to action, acting as secretariat for the working group, facilitating administrative duties, and guiding strategic vision for the long-term advocacy effort. A seed grant was awarded to the lead agency to support forum preparation. An initial strategy session was held, which resulted in a logic model and project plan.

APPLICATION OF FRAMEWORK

Table 1 lists key aspects of the logic model for both pilots implementing the framework. As Clark and Stovall note, there is a necessary process to transition from a cancer survivor to an advocate, which “requires development of new skills, such as information seeking, communication, problem solving, and negotiation.” For patients and NGOs to be effective change agents, it is critical that they possess the competences to communicate with researchers and providers as well as policymakers and media. The framework incorporates in-person trainings on topics including:

- Grassroots advocacy fundamentals
- Identifying and prioritizing issues and solutions
- Crafting and delivering messages
- Creating and launching a national call to action
- Action planning (grassroots campaign and patient forum)

In the 12 months after initial trainings, ongoing technical assistance was provided, and the local working group produced outputs including but not
limited to: vision for the goals and objectives of the forum, agenda, fundraising strategy, community engagement activities, dissemination plan for the call to action (including social media strategy), and a monitoring and evaluation plan. Additional in-person media trainings were also conducted before the forum launch.

RESULTS

Table 2 lists the outcomes of both pilot projects. It is acknowledged that evaluating advocacy is inherently challenging and requires a different approach than evaluation of programs, given the nonlinear nature of advocacy efforts and the rapidly changing environment in which they occur. In addition, best practices in advocacy evaluation articulate that measurement of intermediate outcomes, such as capacity building, is just as critical as assessment of a final outcome, such as policy change. Given this and the fact that long-term results in both countries are still being assessed, our results focus mostly on short- and intermediate-term impacts.

Results illustrate that the framework empowered organizations and patients to create and launch a national call to action on cancer through implementing a patient forum. Although the sharing of patient voices can happen in a variety of settings, the structure of the framework as an advocacy tool makes it a unique mechanism for patients to share their experiences in a setting that ultimately can contribute toward addressing patient needs through increasing community awareness and mobilization, improving services and resources, and changing policy over time. Involving patients and caregivers in the advocacy process brings a human face and a compelling urgency to addressing cancer, and integrating the voices of marginalized populations helps to ensure that cancer control strategies are person centered.

These results build on the small-wins approach, which posits that successes in advocacy that unfold in an incremental fashion are needed because they “can set in motion forces that can lead to increased higher level interventions”8p313; the results we saw in South Africa and Japan are small wins and are indicative that with continued advocacy activity, greater impact is a possible trajectory.

There are several examples of similar models of cancer advocacy implemented in the United States over the last decade illustrating longer term impact. Two examples are summarized in Table 3. Models like those of the Adolescent and Young Adult Oncology Progress Review Group and the National Action Plan for Cancer Survivorship, which employed frameworks similar to that of the IPAF through multistakeholder collaboration and inclusion of patient voices, present compelling evidence to demonstrate the potential of this type

### Table 1 – Logic Model for Pilot Projects in South Africa and Japan

| Factor          | Description                                                                 |
|-----------------|------------------------------------------------------------------------------|
| Goals           | Empower patients to engage in policy making process; raise awareness among policymakers, general public, health care providers, and media about challenges faced by patients with cancer |
| Objectives      | Implement cancer patient forums with planning committee of NGOs that provides data and information about cancer, raises awareness of select cancer issues, and provides case for improving resources and infrastructure to address cancer issues and break down social stigmas associated with cancer |
| Timeframe       | 18 months                                                                   |
| Inputs          | Training materials, human capital, funding, office infrastructure and supplies |
| Activities      | Training and education, patient forum, national call to action, stakeholder collaboration, patient mobilization |
| Outputs         | Stakeholder meeting held; two to three trainings held; patient forum hosted; national call to action launched and disseminated; media campaign implemented |
| Potential short-term outcomes | Trained patients empowered to share their stories; media trained to include patient voice; increase in knowledge of general public about patient experiences; improved relationships between journalists and NGOs and journalists and patients; national call to action reaches cancer control policymakers; patient advocates engage with key policymakers |
| Potential intermediate-term outcomes | Increase in media coverage and exposure for patient stories; increased collaboration among NGOs; increase in corporate engagement in advocacy efforts |
| Potential long-term outcomes | Needs of patients with cancer addressed at national level through improvements in attitudes, knowledge, practice, policy, systems, and services; increased social support and reduced social stigma and discrimination for people affected by cancer |

Abbreviation: NGO, nongovernmental organization.
of patient advocacy approach for program and policy development and improvement in cancer care and control.

The South African forum marked the first time to our knowledge that patients, civil society, policymakers, and health care providers gathered to engage in dialogue about cancer control. In the follow-up survey, one member of the working group in South Africa noted that the greatest success of the forum was that “government attended and heard our voices.” The forum and call to action marked important first steps on the road toward policymakers considering patient views in the policymaking process. This is consistent with the idea that “government leaders often recognize the value of responding to the needs of their constituents ... when those needs become highly visible,” and “finding ways of genuinely involving cancer [survivors] will greatly strengthen advocacy in the long run.”

In Japan, stakeholders sought to build awareness of the challenges that patients face among the public and create a base of informed community members who could mobilize to support a grassroots campaign.

| Goals of Framework | South Africa                                                                 | Japan                                                                 |
|--------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Short-term outcomes| Trained patients empowered and prepared to share their stories at forum     | 11 patients trained and shared stories at forum                       |
|                    | NGO working group prepared to implement patient forum                       | Patient forum held                                                   |
|                    | Creation and release of call to action on cancer                             | Call to action on cancer written and released                        |
| Intermediate-outcome| Increase in attention for cancer issues and patient voices                  | > 34 articles and interviews published about survivor stories and call to action after its release |
|                    | Increased collaboration; new partnerships                                   | Formation of first cancer alliance in country by NGOs and patient representatives |
|                    | Participation of civil society in policy discussions with decisionmakers and/or growth of patient-driven grassroots movement | Cancer alliance invited to join and actively participating in Ministerial Advisory Committee on Cancer |
|                    | Needs of patients with cancer addressed at national level through improvements in attitudes, knowledge, practice, policy, systems, services | Cancer survivors invited to formally partner with government and are sharing stories with local communities in cancer awareness efforts |
| Long-term outcomes | Development of new national cancer control policies; government commitment to develop national breast cancer policy and ensure national cancer registry is mobilized and adequately resource | Development of new national cancer control policies; government commitment to develop national breast cancer policy and ensure national cancer registry is mobilized and adequately resource |

Abbreviations: IPAF, International Patient Advocacy Framework; NGO, nongovernmental organization; OCT, Over Cancer Together.
Results such as the ongoing inclusion of patient voices in media postforum and release of the call to action and growth of the related Over Cancer Together campaign indicate early success. These results are echoed in the literature, which notes that a critical aspect of advocacy is strategic communication, which informs community about challenges and mobilizes it to find solutions collaboratively.4 The framework supported both country initiatives in achieving their different goals: a grasstops approach in South Africa and a grassroots approach in Japan. We suggest that this occurred as a result of several critical success factors, summarized in Table 4.

**DISCUSSION**

Patient advocacy can be challenging as a result of stigma, which acts as a significant barrier to accurate surveillance (because of individuals fearing diagnosis or treatment)39 and has led to challenges in survivors sharing their cancer experiences for fear of judgment or discrimination. In some cases, the storytelling training can act as a means to reduce stigma; however, stigma and fear may prevent patients and survivors from desiring to participate. That being said, the inclusion of raw, powerful patient stories in both countries was a significant contributor to success of the model because of the transportation effects of storytelling. This supports existing data suggesting that stories can change attitudes and affect beliefs and action “by presenting emotionally powerful information along with vivid mental images, while reducing counter arguing.”36pS175 The WHO notes that “coalition building ... and social mobilization are critical to the success of advocacy efforts”4p19; in addition, “involving health-care professionals and researchers is also critical as this ensures that advocacy plans are evidence-based and relevant.”4p7 Furthermore, experts state that ultimately, the benefits of collaboration in advocacy include “a reduction in redundancy of services, conservation of human and financial resources ... and a population of survivors who are empowered and engaged advocates.”7p2313 However, cultivating meaningful collaboration between NGOs and other stakeholders is a challenging and nuanced endeavor as a result of competition (for funding, awareness, and public engagement) and competing priorities. We found that it is critical for...
partnering NGOs to build trust and find a shared vision of ultimate benefit for all partners, one that surmounts individual organizational goals toward a more powerful common agenda.

There are limitations to our framework. One is the fact that it has only been tested in two countries. We anticipate that additional testing in other regions will be valuable in further demonstrating the impact of the framework as a global model.

As discussed previously, it was determined at the outset of both pilots that we would only measure the short- and intermediate-term impacts. It was requested that lead agencies work collaboratively to track and share long-term impacts, but this was not required. As such, these results largely reflect the short- and intermediate-term impacts, because long-term outcomes are still being assessed by lead agencies. Despite this, initial impacts strongly suggest that with continued advocacy activity, stakeholders are making notable progress toward seeing long-term impacts. Another limitation is the lack of data collected from patients who participated in the projects. The scale of our evaluation limited us to surveying lead agencies with which we worked directly. In addition, given the complexities of policy and system change in particular, the framework should be viewed as a mechanism to contribute to long-term outcomes, as opposed to being the sole factor to which long-term outcomes are attributed.

In conclusion, given our results, the work by Durtine and Leitman,25 and illness narrative studies like that by Green,36 we suggest that there is an opportunity to further study the effects of patient storytelling on personal and collective empowerment and its influence on disclosure of diagnosis, contributing to reduction of stigma. On the basis of limited qualitative data collected from participants in the Japanese training, it is suggested that the framework benefitted patients by providing a meaningful way to engage in the fight against cancer, connect with other patients in a supportive setting, and to heal and find meaning in the cancer journey.36 We suggest that future research explore the impact of patient storytelling globally as a means of social support and psychosocial healing as well as its impact on influencing others to engage in grassroots advocacy.

On the basis of these results, we believe that the IPAF is globally relevant and could be adapted and implemented in other countries to amplify patient voices in the policymaking process, increase grassroots mobilization, improve health systems through addressing patient needs, and ultimately support countries in meeting NCD and cancer control targets. Further research is also needed on the long-term impacts of cancer patient advocacy; it would be particularly beneficial to see other countries implement the framework and track outcomes longitudinally. Ultimately, people will benefit if health systems globally can evolve toward a place of sustained and meaningful patient participation and engagement.

DOI: 10.1200/JGO.2015.000398

Table 4 – Critical Success Factors for Implementation of IPAF

| Factor | Description |
|--------|-------------|
| Historical precedent and cultural value of advocacy in country* | History of and cultural value for concept; if country has little to no history of advocacy, it may be more challenging to develop understanding of concept and nuances; if advocacy has limited cultural value or is contrary to political structures in country, basic tenets of advocacy strategy may have limited utility, or it may take larger-scale effort to see results |
| Basic cancer care infrastructure† | Some level of existing cancer control plans and systems; if country has little infrastructure to detect or treat cancer, there are likely lower rates of survivorship, which can pose challenge when building base of advocates |
| Existence of organizations with basic knowledge of and interest in advocacy | Organizations that are invested in and have some knowledge of cancer advocacy; furthermore, working with organizations that already pursue some type of advocacy activity will increase likelihood of sustainability |
| Media infrastructure‡ | Basic traditional and new media infrastructure; success in building grassroots movement largely depends on leveraging media to bring awareness to patient stories and issues being raised |

Abbreviation: IPAF, International Patient Advocacy Framework.

*South Africa in particular has a robust history of HIV/AIDS advocacy.
†Japan in particular has evolved cancer care infrastructure.
‡Research has established that “successful advocacy includes use of the media to educate the public on key problems and issues as well as the strategies to address these problems . . . and is thought to play a significant role in shaping public opinion, which in turn may shape the policy agenda.”38p294

Published online ahead of print at jgo.ascopubs.org on October 28, 2015
AUTHOR CONTRIBUTIONS

Manuscript writing: All authors
Final approval of manuscript: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Rebekkah M. Scheer
No relationship to disclose

Leigh Manasco
No relationship to disclose

Devon McGoldrick
No relationship to disclose

Kiti Kajana
No relationship to disclose

Lauren Rosenthal
No relationship to disclose

Ann McMikel
No relationship to disclose

Nancy Lins
No relationship to disclose

ACKNOWLEDGMENT

We thank the Union for International Cancer Control and its members for supporting the crafting of this article as we explored their past programs and Loyce Pace for her expert contributions during the editing and review processes.

REFERENCES

1. World Health Organization: Cancer: Key facts. http://www.who.int/mediacentre/factsheets/fs297/en

2. Selig WKD, Jenkins KL, Reynolds SL, et al: Examining advocacy and comprehensive cancer control. Cancer Causes Control 16:61-68, 2005 (suppl 1)

3. Odedina FT, Rodrigues B, Raja P: Setting the stage for cancer advocacy in Africa: How? Infect Agent Cancer 8:56, 2013 (suppl 1)

4. World Health Organization: Cancer Control: Knowledge Into Action—WHO Guide for Effective Programmes Policy and Advocacy. WHO Press, Geneva, Switzerland, 2008

5. World Health Organization: Global Action Plan for the Prevention and Control of Noncommunicable Diseases: 2013-2020. http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf

6. Union for International Cancer Control: World Cancer Declaration 2013. http://www.uicc.org/sites/main/files/private/131119_UICC_WorldCancerDeclaration_2013_1.pdf

7. McGoldrick D, Gordon P, Whiteson M, et al: Awareness and advocacy for adolescents and young adults with cancer. Cancer 117:2311-2315, 2011 (suppl 10)

8. Jason LA: Small wins matter in advocacy movements: Giving voice to patients. Am J Community Psychol 49: 307-316, 2012

9. Kyriakides S: Psychosocial issues in young women facing cancer and pregnancy: The role of patient advocacy, in Surbonne A, Peccatori F, Pavlidis N (eds): Cancer and Pregnancy. Berlin, Germany, Springer, 2008, pp 247-252

10. Reference deleted

11. Clark EJ, Stovall EL: Advocacy: The cornerstone of cancer survivorship. Cancer Pract 4:239-244, 1996

12. Toofany S: Patient empowerment: Myth or reality. Nurs Manage (Harrow) 13:18-22, 2006

13. Davis C, Saio L, Redman S: Evaluating the effectiveness of advocacy training for breast cancer advocates in Australia. Eur J Cancer Care (Engl) 10:82-86, 2001

14. Hoffman B, Stovall E: Survivorship perspectives and advocacy. J Clin Oncol 24:5154-5159, 2006

15. Fricker J: Patient advocacy groups: Empowering patients in their fight against cancer. Mol Oncol 1:252-254, 2007

16. Perlmutter J, Bell SK, Darien G: Cancer research advocacy: Past, present, and future. Cancer Res 73:4611-4615, 2013

17. Braun S: The history of breast cancer advocacy. Breast J 9:S101-S103, 2003 (suppl 2)

18. Errico KM, Rowden D: Experiences of breast cancer survivor-advocates and advocates in countries with limited resources: A shared journey in breast cancer advocacy. Breast J 12:S111-S116, 2006

19. Redmond K: Collaboration with patient advocates: Unleashing a potent force. BJU Int 91:590-591, 2003

20. Osborn R, Squires D: International perspectives on patient engagement: Results from the 2011 Commonwealth Fund Survey. J Ambul Care Manage 35:118-128, 2012

21. Carman KL, Dardess P, Maurer M, et al: Patient and family engagement: A framework for understanding the elements and developing interventions and policies. Health Aff (Millwood) 32:223-231, 2013
22. World Health Organization: Cancer Control: Knowledge Into Action—WHO Guide for Effective Programmes. Geneva, Switzerland, WHO Press, 2006
23. Odedina FT, Rodrigues B: Cancer advocacy in Africa: Case studies of innovative practices. Infect Agent Cancer 8:S7, 2013
24. Azenha G, Bass LP, Caleffi M, et al: The role of breast cancer civil society in different resource settings. Breast 20:S81-S87, 2011
25. Durstine A, Leitman E. Building a Latin American cancer patient advocacy movement: Latin American cancer NGO regional overview. Salud Publica Mex 51:S316-S322, 2009
26. Farmer P, Frenk J, Knaul FM, et al: Expansion of cancer care and control in countries of low and middle income: A call to action. Lancet 376:1186-1193, 2010
27. World Health Organization: Global health observatory data repository: Policies, strategies, and action plans—Data by country. http://apps.who.int/gho/data/node.main.A907?lang=en
28. Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries: Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries. http://gtfccc.harvard.edu/fs/docs/icb.topic1063570.files/ccd_report_111027.pdf
29. Miller K, Simon M (eds): Global Perspectives on Cancer: Incidence, Care and Experience (vols 1-2). Santa Barbara, CA, ABC-CLIO, 2015
30. Quale DZ, Droller MJ: Cancer patient advocacy: New opportunities for treatment advances. Urol Oncol 25:351-352, 2007
31. Lins N: Patient forums. Union for International Cancer Control, Geneva, Switzerland, 2004
32. Teles S, Schmitt M: The elusive craft of evaluating advocacy. Stanford Soc Innov Rev 39-44, 2011
33. Jackson A: Evaluation of public policy advocacy: Challenges, principles and BEST-AC case study. Int J Public Sect Manag 27:272-280, 2014
34. Devlin-Foltz D, Fagen MC, Reed E, et al: Advocacy evaluation: Challenges and emerging trends. Health Promot Pract 13:581-586, 2012
35. Coffman J: What’s different about evaluating advocacy and policy change? http://www.hfrp.org/evaluation/the-evaluation-exchange/issue-archive/advocacy-and-policy-change/what-s-different-about-evaluating-advocacy-and-policy-change
35a. Smith JL, Pollack L, Rodriguez JL, et al: Assessment of the status of a national action plan for cancer survivorship in the USA. http://www.ncbi.nlm.nih.gov/pubmed/23609522
36. Green MC: Narratives and cancer communication. J Commun 56:S163-S183, 2006
37. Mathews-Bradshaw B, Craddock K, Rechis-Oelker R, et al: Summary report of the LIVESTRONG Young Adult Alliance Implementation Plan. Austin, TX, LIVESTRONG Foundation, 2011
38. Gardner A, Geierstanger S, Brindis C et al: Clinic consortia media advocacy capacity: Partnering with the media and increasing policymaker awareness. J Health Commun 15:293–306, 2010
39. Neal C, McGoldrick D, Scheur R: The experience of stigma: Impacts and implications, in Miller KD, Simon M (eds): Global Perspectives on Cancer: Incidence, Care and Experience (ed 1). Santa Barbara, CA, ABC-CLIO, 2015, pp 41-53